November 2026—The FDA has cleared Qiagen’s QIAstat-Dx BCID GPF Plus AMR panel, the first QIAstat-Dx panel for bloodstream infections to receive FDA clearance. The panel detects 20 Gram-positive bacterial and fungal pathogen targets as well as a broad pan Gram-negative target together with 10 genetic antimicrobial resistance markers from positive blood culture samples in about one hour. A complementary QIAstat-Dx BCID GN Plus AMR panel, designed to detect Gram-negative pathogens and associated genetic antimicrobial resistance markers, is under FDA review.
Qiagen, 800-426-8157